NCT01866553 - Nilotinib Plus Pegylated Interferon-α2b in CML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 8, 2016

Study Completion Date

May 1, 2016

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG

Nilotinib

300 mg capsule BID oral use

DRUG

Pegylated interferon α-2b

25 - 40 microgram per week for subcutaneous use

Trial Locations (5)

Aarhus University Hospital, Aarhus

Helsinki University Hospital, Helsinki

VU University Medical Center, Amsterdam

Trondheim University Hospital, Trondheim

Uppsala University Hospital, Uppsala